RxDoctor Payments Data

Mercelline Mugalla, NP

Psychiatric/Mental Health · Austin, TXNPI 1316222417

Payments from drug & device makers

$509in general payments, 2019–2025

Across 14 payments — averaging $36.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$160
  • Alkermes, Inc.$116
  • Neurocrine Biosciences, Inc.$63
  • Teva Pharmaceuticals USA, Inc.$49
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$42
  • E.r. Squibb & Sons, L.L.C.$27
  • plus $52 from 2 others

What the payments were for

  • Food & beverage$48295%
  • Education$275%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$509 in reported general payments places this provider in the 45th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$9,566
Medicare patients
55
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$42,391
Abilify MaintenaAripiprazole13$34,166
RexultiBrexpiprazole12$17,384
Paxil CrParoxetine Hcl12$10,323
Lurasidone Hcl70$6,628
Lisdexamfetamine Dimesylate26$5,689
TrintellixVortioxetine Hydrobromide45$4,717
Ziprasidone Hcl77$3,132
Quetiapine Fumarate179$2,878
Duloxetine Hcl137$2,574
Lamotrigine173$2,239
Aripiprazole102$2,063
Divalproex Sodium50$1,920
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine41$1,830
Buspirone Hcl170$1,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$160$51,55025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →